%0 Journal Article
%T A recurrent missense variant in ITPR3 causes demyelinating Charcot-Marie-Tooth with variable severity.
%A Beijer D
%A Dohrn MF
%A Rebelo A
%A Danzi MC
%A Grosz BR
%A Ellis M
%A Kumar KR
%A Vucic S
%A Vais H
%A Weissenrieder JS
%A Lunko O
%A Paudel U
%A Simpson LC
%A Raposo J
%A Saporta M
%A Arcia Y
%A Xu I
%A Feely S
%A Record CJ
%A Blake J
%A Reilly MM
%A Scherer S
%A Kennerson M
%A Lee YC
%A Foskett JK
%A Shy M
%A Zuchner S
%J Brain
%V 0
%N 0
%D 2024 Jun 28
%M 38938188
%F 15.255
%R 10.1093/brain/awae206
%X Charcot-Marie-Tooth (CMT) disease is a neuromuscular disorder affecting the peripheral nervous system. The diagnostic yield in demyelinating CMT (CMT1) is typically ∼80-95%, of which at least 60% is due to the PMP22 gene duplication. The remainder of CMT1 is more genetically heterogeneous. We used whole exome and whole genome sequencing data included in the GENESIS database to investigate novel causal genes and mutations in a cohort of ∼2,670 individuals with CMT neuropathy. A recurrent heterozygous missense variant p.Thr1424Met in the recently described CMT gene ITPR3, encoding IP3R3 (inositol 1,4,5-trisphosphate receptor 3) was identified. This previously reported p.Thr1424Met change was present in 33 affected individuals from nine unrelated families from multiple populations, representing an unusual recurrence rate at a mutational hotspot, strengthening the gene-disease relationship (GnomADv4 allele frequency 1.76e-6). Sanger sequencing confirmed the co-segregation of the CMT phenotype with the presence of the mutation in autosomal dominant and de novo inheritance patterns, including a four-generation family with multiple affected second-degree cousins. Probands from all families presented with slow nerve conduction velocities, matching the diagnostic category of CMT1. Remarkably, we observed a uniquely variable clinical phenotype for age at onset and phenotype severity in p.Thr1424Met carrying patients, even within families. Finally, we present data supportive of a dominant-negative effect of the p.Thr1424Met mutation with associated changes in protein expression in patient-derived cells.